Advances in Ovarian Cancer Treatment: Past, Present and Future

Dear Colleagues,

Ovarian cancer is the most lethal gynecological malignancy in relation to cervical and endometrial cancers. It is associated with the worst prognosis and a high mortality rate. In most cases (75%), ovarian cancer is diagnosed at an advanced stage due to its asymptomatic and silent growth of the tumor, delayed onset of symptoms and lack of proper screening.

 However, important steps have been made in the treatment of advanced ovarian cancer concerning surgery, adjuvant or neoadjuvant chemotherapy drug regiments and maintenance targeted therapy. These resulted in an improved progression-free and overall survival, and a better quality of life of these patients. Nevertheless, even with the new treatment improvements, 80% of the patients will experience recurrence.

This Special Issue aims to highlight the current practice and advances in ovarian cancer treatment, including cytoreductive surgery, HIPEC, new chemotherapeutic agents and maintenance targeted therapy.

Dr. Dimitrios Tsolakidis
Dr. Dimitrios Zouzoulas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ovarian cancer
• cytoreductive surgery
• HIPEC
• chemotherapy
• immunotherapy